267 related articles for article (PubMed ID: 18097693)
1. RNA interference of LRRK2-microarray expression analysis of a Parkinson's disease key player.
Häbig K; Walter M; Poths S; Riess O; Bonin M
Neurogenetics; 2008 May; 9(2):83-94. PubMed ID: 18097693
[TBL] [Abstract][Full Text] [Related]
2. Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.
Gandhi PN; Chen SG; Wilson-Delfosse AL
J Neurosci Res; 2009 May; 87(6):1283-95. PubMed ID: 19025767
[TBL] [Abstract][Full Text] [Related]
3. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
[TBL] [Abstract][Full Text] [Related]
4. Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways.
Sancho RM; Law BM; Harvey K
Hum Mol Genet; 2009 Oct; 18(20):3955-68. PubMed ID: 19625296
[TBL] [Abstract][Full Text] [Related]
5. LRRK2 guides the actin cytoskeleton at growth cones together with ARHGEF7 and Tropomyosin 4.
Häbig K; Gellhaar S; Heim B; Djuric V; Giesert F; Wurst W; Walter C; Hentrich T; Riess O; Bonin M
Biochim Biophys Acta; 2013 Dec; 1832(12):2352-67. PubMed ID: 24075941
[TBL] [Abstract][Full Text] [Related]
6. Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease.
Seol W
BMB Rep; 2010 Apr; 43(4):233-44. PubMed ID: 20423607
[TBL] [Abstract][Full Text] [Related]
7. LRRK2 Structure-Based Activation Mechanism and Pathogenesis.
Zhang X; Kortholt A
Biomolecules; 2023 Mar; 13(4):. PubMed ID: 37189360
[TBL] [Abstract][Full Text] [Related]
8. LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.
Xiong Y; Dawson VL; Dawson TM
Biochem Soc Trans; 2012 Oct; 40(5):1074-9. PubMed ID: 22988868
[TBL] [Abstract][Full Text] [Related]
9. Leucine-rich repeat kinase 2: relevance to Parkinson's disease.
Guo L; Wang W; Chen SG
Int J Biochem Cell Biol; 2006; 38(9):1469-75. PubMed ID: 16600664
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications.
Rudenko IN; Cookson MR
Neurotherapeutics; 2014 Oct; 11(4):738-50. PubMed ID: 24957201
[TBL] [Abstract][Full Text] [Related]
11. Molecular biology changes associated with LRRK2 mutations in Parkinson's disease.
Lu YW; Tan EK
J Neurosci Res; 2008 Jul; 86(9):1895-901. PubMed ID: 18338801
[TBL] [Abstract][Full Text] [Related]
12. LRRK2 in Parkinson's disease: protein domains and functional insights.
Mata IF; Wedemeyer WJ; Farrer MJ; Taylor JP; Gallo KA
Trends Neurosci; 2006 May; 29(5):286-93. PubMed ID: 16616379
[TBL] [Abstract][Full Text] [Related]
13. Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.
Kramer T; Lo Monte F; Göring S; Okala Amombo GM; Schmidt B
ACS Chem Neurosci; 2012 Mar; 3(3):151-60. PubMed ID: 22860184
[TBL] [Abstract][Full Text] [Related]
14. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
Illarioshkin SN; Shadrina MI; Slominsky PA; Bespalova EV; Zagorovskaya TB; Bagyeva GKh; Markova ED; Limborska SA; Ivanova-Smolenskaya IA
Eur J Neurol; 2007 Apr; 14(4):413-7. PubMed ID: 17388990
[TBL] [Abstract][Full Text] [Related]
15. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity.
West AB; Moore DJ; Biskup S; Bugayenko A; Smith WW; Ross CA; Dawson VL; Dawson TM
Proc Natl Acad Sci U S A; 2005 Nov; 102(46):16842-7. PubMed ID: 16269541
[TBL] [Abstract][Full Text] [Related]
16. The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites.
Greggio E; Taymans JM; Zhen EY; Ryder J; Vancraenenbroeck R; Beilina A; Sun P; Deng J; Jaffe H; Baekelandt V; Merchant K; Cookson MR
Biochem Biophys Res Commun; 2009 Nov; 389(3):449-54. PubMed ID: 19733152
[TBL] [Abstract][Full Text] [Related]
17. Leucine-rich repeat kinase 2 associates with lipid rafts.
Hatano T; Kubo S; Imai S; Maeda M; Ishikawa K; Mizuno Y; Hattori N
Hum Mol Genet; 2007 Mar; 16(6):678-90. PubMed ID: 17341485
[TBL] [Abstract][Full Text] [Related]
18. Leucine-rich repeat kinase 2 and alternative splicing in Parkinson's disease.
Elliott DA; Kim WS; Gorissen S; Halliday GM; Kwok JB
Mov Disord; 2012 Jul; 27(8):1004-11. PubMed ID: 22528366
[TBL] [Abstract][Full Text] [Related]
19. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.
Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW
Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787
[TBL] [Abstract][Full Text] [Related]
20. LRRK2 links genetic and sporadic Parkinson's disease.
Kluss JH; Mamais A; Cookson MR
Biochem Soc Trans; 2019 Apr; 47(2):651-661. PubMed ID: 30837320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
